Richard Hall headshot
RH

Richard Delmar Hall

Associate Professor
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
Education
Clinical Fellowship, Hematology-Oncology, H. Lee Moffitt Cancer Center and Research Institute
MD, University of Texas Southwestern Medical Center
Residency, University of Virginia
Chief Resident, University of Virginia
MS, Clinical & Translational Research, University of South Florida
Biography

Richard D. Hall, MD, MS is a native of Texas, where he attended Texas A&M University and completed medical school at the University of Texas Southwestern in Dallas. He completed his internal medicine residency at the University of Virginia in 2010 and went on to serve as a chief resident at UVA in 2010-2011. Dr. Hall completed his fellowship training at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL, in 2014. As a fellow, he attended the American Association for Cancer Research Molecular Biology Workshop in Snowmass, CO, and completed a Master of Science degree in clinical and translational research at the University of South Florida. 

Dr. Hall joined the UVA School of Medicine faculty and UVA Cancer Center in 2014. He specializes in the treatment of thoracic malignancies, including non-small-cell lung cancer, small-cell lung cancer, thymic malignancies and mesothelioma. His primary research focus is the application of novel therapeutics, including immunotherapy, antibody drug conjugates, tyrosine kinase inhibitors and combination therapies for the treatment of lung cancer. Dr. Hall has been the UVA principal investigator on multiple lung cancer clinical trials since joining the faculty. In addition to his clinical work, Dr. Hall is involved in the educational leadership of the internal medicine residency program and became the hematology/oncology fellowship program director in August 2017.

PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)
Source: Daiichi Sankyo, Inc
June 10, 2021 – June 09, 2024
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
Source: Hoosier Cancer Research Network, Inc.
November 25, 2020 – November 24, 2023
INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO
Source: Alliance for Clinical Trials in Oncology Foundatio
September 01, 2020 – August 31, 2023
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Source: ECOG-ACRIN Cancer Research Group
May 18, 2020 – May 17, 2023
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Source: Hoosier Cancer Research Network, Inc.
April 21, 2020 – April 20, 2023
MD-INMD-HO-Hall ETCTN 10166 - A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Source: Johns Hopkins University
September 01, 2018 – February 28, 2023
A Phase I/II Study of AZD9291 and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer
Source: Johns Hopkins University
May 01, 2020 – February 28, 2023
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with
Source: Mirati Therapeutics, Inc.
December 18, 2019 – December 17, 2022
A Biomarker-Driven Protocol for Previously Treated NSCLC ALK Positive Patients: The NCI-NRG-ALK Protocol
Source: NRG Oncology Foundation, Inc.
August 20, 2019 – August 19, 2022
LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB
Source: NRG Oncology Foundation, Inc.
July 19, 2019 – July 18, 2022
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
Source: ECOG-ACRIN Cancer Research Group
March 14, 2019 – March 13, 2022
Outcomes of Osimertinib in Patients with EGFR+ Advanced Non-Small Cell Lung Cancer: A Multi-Site Observational Study Across Comprehensive Cancer Centers
Source: University of Utah
November 13, 2019 – December 31, 2021
Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.
Source: Alliance Foundation Trials, LLC.
August 17, 2017 – July 22, 2021
MD-INMD-HO - S1800A -Hall - A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Su
Source: ECOG-ACRIN Cancer Research Group
November 01, 2019 – March 10, 2021
A phase II study of olaparib plus cediranib in combination with standard therapy for small cell lung cancer
Source: Johns Hopkins University
June 01, 2017 – February 28, 2021
A Pilot Study to Detect Circulating Tumor Cells (CTCs) and Cancer Derived Material (CDM) in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC)
Source: Axon Dx, LLC
November 01, 2017 – October 31, 2020
MD-INMD A Phase II Study of the Combination of LY3023414 and Necitumumab after First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Source: SCRI Services, LLC
July 22, 2015 – July 31, 2020
A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment...
Source: Merck Sharp & Dohme Corp.
January 09, 2018 – April 17, 2020
MD-INMD A Phase 2 Study of Rovalpituzumab Tesirine(SC16LD6.5)for Third-Line Treatment of Subjects w/Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer(TRINITY)
Source: AbbVie Inc.
April 15, 2016 – March 31, 2020
MD-INMD-HO Hall LUN15-233
Source: Hoosier Cancer Research Network, Inc.
July 09, 2018 – September 24, 2019
MD-INMD-HO A Phase II Study of the Combination of LY3023414 and Necitumumab after First-Line Chemotherapy for Metastatic Squamous Non-Small Cell Carcinoma of the Lung
Source: SCRI Development Innovations, LLC
July 22, 2015 – May 24, 2018
A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
Source: Bristol-Myers Squibb Company
June 29, 2017 – October 11, 2017